6719 abstracts found.



Results filter

High-throughput miRNA-inhibitors screening identified selected miRNAs involved in the modulation of FOLFIRINOX chemotherapy in pancreatic cancer

Year:

Session type:

Theme:

Domenico Zito1,Rosantony Pandolfo2,Pietro Carotenuto2,Matteo Fassan3,Andrea Lampis2,Maria Chiara Previdi2,Francesco Sclafani4,Andrea Lanese4,Ian Huntingford2,Jens C Hahne2,Kate Young4,Ruwaida Begum4,Zakaria Ethiar4,Blanka Hazelova4,Andrew Wotherspoon4,Sheela Rao4,David Watkins4,Naureen Starling4,Anguraj Sadanandam2,David Cunningham4,Ian Chau4,Paul Workman2,Nicola Valeri5,Chiara Braconi5
1The Institute of Cancer Research,2The Institute of Cancer Research, London, UK,3University of Padua, Italy,4The Royal Marsden NHS Trust London and Surrey, UK,5The Institute of Cancer Research, London, UK / The Royal Marsden NHS Trust London and Surrey, UK

Assessing the stability of clinically relevant prognostic, predictive and subtyping gene expression signatures based on intra-tumoural heterogeneity in colorectal cancer

Year:

Session type:

Theme:

Philip Dunne1,Paul O'Reilly2,Susan Richman3,Elaine Kay4,Manuel Salto-Tellez2,Patrick Johnston2,Darragh McArt2,Mark Lawler2
1CCRCB Queen's University Belfast,2Centre for Cancer Research and Cell Biology, Queen's University Belfast,3Leeds Institute of Cancer and Pathology,4Beaumont Hospital and Royal College of Surgeons in Ireland

Evaluation of Average Intensity Projection (AvIP) in outlining a planning target volume for oesophageal cancer patients

Year:

Session type:

Theme:

Ganesh Radhakrishna1,Patrick Murray1,Rebecca Goody1,Andrew Scarsbrook1,Robin Prestwich1,Sarah Wright1,Garry McDermott1,Ganesh Radhakrishna2
1Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust,2Leeds Cancer Centre

Lancashire and South Cumbria Cancer Network (LSCCN) experience of nab-paclitaxel (Abraxane) and gemcitabine in the treatment of metastatic pancreatic cancer

Year:

Session type:

Theme:

Janice Tan1,Catherine Mitchell1,Catherine Thompson2,Ana Ferreira Ferreira3,David Fyfe2,Elaine Young1
1Lancashire Teaching Hospitals NHS Foundation Trust,2University Hospitals of Morecambe Bay NHS Foundation Trust,3East Lancashire Hospitals NHS Trust

Use of haematological and biochemical parameters to identify paraproteinaemia patients in need of further investigations to rule out myeloma

Year:

Session type:

Theme:

Tom Bull1,George Vassiliou2,Joao Dias2,Conor O'Donovan3
1Addenbrookes NHS Foundation Trust,2Cambridge University,3West Suffolk Hospital NHS Trust

What is the most commonly prescribed treatment for metastatic endometrial cancer in the second line setting in the UK, and how effective is this treatment?

Year:

Session type:

Theme:

Magdalena Meissner1,Axel Walther1
1Bristol Cancer Institute, University Hospitals Bristol Foundation NHS Trust

Short-course radiotherapy followed by neo-adjuvant chemotherapy in rectal cancer with synchronous liver metastases: a single institution experience.

Year:

Session type:

Theme:

Mark Teo1,Fei Sun2,Nathalie Casanova2,Rachel Cooper2,David Sebag-Montefiore1
1University of Leeds,2Leeds Cancer Centre

Is there a role for palliative pelvic radiotherapy in pelvic symptom control in metastatic/unresectable rectal cancer?

Year:

Session type:

Theme:

Mark Teo1,Yanos Reynolds-Khan2,Victor Chew2,Daniel Swinson2,David Sebag-Montefiore1
1University of Leeds,2Leeds Cancer Centre

Early outcomes in stereotactic body radiotherapy (SBRT) for metastatic breast cancer: an analysis of toxicity and local control.

Year:

Session type:

Theme:

Daniel Henderson1,Anna Kirby2,Imogen Locke2,Gillian Ross2,Diana Tait2,Alison Tree2,Vincent Khoo2,Nicholas van As2
1,2Royal Marsden Hospital

Cytotoxic pimarane diterpenes from Juniperus servaschanica

Year:

Session type:

Theme:

Md Sohail Akhtar1,Sadri Abdullah Said1,Yahya Tamimi2,Afaf Mohd Weli1,Qassim Ahmed Alriyami1,Suleiman Said Alkhanjari1
1University of Nizwa,2Sultan Qaboos University

Detection of Circulating Tumour Cells for use as Prognostic, Predictive and Pharmacodynamic biomarkers in Neuroblastoma

Year:

Session type:

Theme:

Swathi Merugu1,Lindi Chen2,David Jamieson2,Deborah Tweddle2
1Newcastle university,2Newcastle University

Conformity analysis of target-volume definition for margin-directed boost in pancreatic cancer SBRT

Year:

Session type:

Theme:

Daniel Holyoake1,Maxwell Robinson2,Derek Grose3,David McIntosh3,David Sebag-Montefiore4,Ganesh Radhakrishna5,Neel Patel2,Somnath Mukherjee2,Mike Partridge1,Maria Hawkins1
1CRUK/MRC Oxford Institute for Radiation Oncology,2Oxford University Hospitals NHS Foundation Trust,3The Beatson West of Scotland Cancer Centre,4CRUK Leeds Centre,5Leeds Cancer Centre

Comparison of three different tumour budding methods to evaluate the prediction of lymph node metastasis in pT1 colorectal carcinomas

Year:

Session type:

Theme:

Scarlet Fiona Brockmoeller1,Eu-Wing Toh2,Eva Morris3,Phil Quirke4
1Leeds Univeristy,21Pathology & Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, UK,32 Cancer Epidermiology Group, Leeds Institute of Cancer and Pathology, University of Leeds, UK,4Pathology & Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, UK

Selectively targeting TSC1/2 deficient cells by exploiting endoplasmic reticulum stress and oxidative stress

Year:

Session type:

Theme:

Mark Davies1,Andrew Tee2,Charlotte Johnson2,Elaine Dunlop2,Henry McCann2
1,2Institute of Cancer and Genetics, Cardiff University, Heath Park, Cardiff CF14 4XN, UK

Clinical and therapeutic significance of Folate receptor alpha (FRα) in ovarian cancer

Year:

Session type:

Theme:

Charleen Chan Wah Hak1,Heather J Bax2,Debra H Josephs3,Alexandra Robinson4,Sadek Malas5,Giulia Pellizzari1,Paul Jones6,Claire Barton6,Hannah J Gould7,Ana Montes8,James Spicer9,Sophia N Karagiannis1
1St John’s Institute Dermatology, Division of Genetics and Molecular Medicine, King’s College London,2St John’s Institute Dermatology, Division of Genetics and Molecular Medicine, King’s College London; Research Oncology, Division of Cancer Studies, King’s College London,3St John’s Institute Dermatology, Division of Genetics and Molecular Medicine, King’s College London; Research Oncology, Division of Cancer Studies, King’s College London; Department of Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust,4GKT School of Medical Education, King’s College London,5Institute of Medical and Biomedical Education, St George’s University of London,6Centre for Drug Development, Cancer Research UK,7Randall Division Cell and Molecular Biology, King’s College London,8Department of Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust,9Research Oncology, Division of Cancer Studies, King’s College London; Department of Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust

A regional audit on the management of ALK positive non-small cell lung cancer patients with crizotinib in the East of England

Year:

Session type:

Theme:

Michelle Smith1,Kent Yip1,Gary Doherty2,Sarah Prewett2,Abigail Hollingdale3,Zacharias Tasigiannopoulos4,Daniel Patterson5,Yvonne Rimmer5,Charlie Ingle6,Kathryn Waite7,Shahzeena Aslam8,Pinelopi Gkogkou4,Alex Martin9,Jamie Morgan1,Susan Harden2,David Gilligan2
1Ipswich hospital,2Addenbrooke's hospital,3Peterborough hospital,4Norfolk and Norwich hospital,5West Suffolk hospital,6Colchester hospital,7Queen Elizabeth hospital, King's Lynn,8Bedford hospital,9Hinchingbrooke hospital

In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B

Year:

Session type:

Theme:

Mohannad Qazzaz1,Vijay Raja2,Daniel Roth3,Natacha Olieric4,Andrea Prota4,Kuan-Hon Lim5,Toh-Seok Kam6,Anne Straube3,Michel Steinmetz4,Tracey Bradshaw1
1University of Nottingham,2Weill Cornell Medicine,3University of Warwick,4Paul Scherrer Institut, Laboratory of Biomolecular Research, Dynamic Protein Interactions, Switzerland,5School of Pharmacy, University of Nottingham Malaysia Campus,6Department of Chemistry, Faculty of Science, University of Malaya

Investigating the impact of busulfan and melphalan exposure on toxicity in high-risk neuroblastoma patients – results from the European HR-NBL1/SIOPEN trial

Year:

Session type:

Theme:

Gareth Veal1,Angelo Paci2,Vianney Poinsignon2,Julie Errington3,Jennifer Bonner3,Claudio Pasqualini2,Dominique Valteau-Couanet2,Martin Elliot4,Deborah Tweddle3,Ruth Ladenstein5
1University of Newcastle,2Institut Gustave Roussy,3Newcastle University,4Leeds General Infirmary,5St Anna Children’s Hospital and Children’s Cancer Research Institute

Application of Next Generation Sequencing in Liquid Biopsy analysis

Year:

Session type:

Theme:

Eirini Papadopoulou1,Vasiliki Metaxa-Mariatou1,Nikolaos Tsoulos1,Angeliki Tsirigoti1,Chrisoula Efstathiadou1,Angela Apessos1,Konstantinos Agiannitopoulos1,Georgia Pepe1,George Nasioulas1
1GeneKor Medical S.A.

Service Review of Liposomal Doxorubicin in Gynaecological Cancers

Year:

Session type:

Theme:

Tony Mathew1,Samantha Gaffing2,Finbar Selvin3,Prashanth Sanganalmath4,Jackie Martin5,Simon Pledge5
1Weston Park Hospital, Sheffield Teaching Hospital,2FY2 doctor. Rotherham, Doncaster, South Humberside NHS Foundation Trust,3ST4 in Clinical Oncology. St James Hospital, Leeds,4ST6 in Clinical Oncology. Weston Park Hospital, Sheffield,5Consultant in Clinical Oncology. Weston Park Hospital, Sheffield

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

Year:

Session type:

Theme:

Victoria Woodcock1,Mark Middleton1,Christian Rolfo2,Elena Elez3,Sandra Van Schaeybroeck4,Julien Taieb5,Jennifer Houlden6,Linda Collins6,Sharon Love7,Corran Roberts7,Thierry André8,Robert Jones9,Mark Lawler10,Federica Di Nicolantonio11,Margaret Grayson12,Alberto Bardelli11,Pierre Laurent-Puig13,Gordon McGregor10,Tim Maughan14,Josep Tabernero3,Marc Peeters2,Richard Wilson4
1University of Oxford, Oxford, UK,2University Hospital Antwerp, Antwerp, Belgium,3Vall d'Hebron Institute of Oncology, Barcelona, Spain,4Queen's University Belfast, Belfast, UK,5Georges Pompidou European Hospital, Paris, France,6Oncology clinical Trials Office, Oxford, UK,7Centre for Statistics in Medicine, Oxford, UK,8Saint-Antoine Hospital, Paris, France,9Velindre Cancer Centre, Cardiff, UK,10Queen’s University Belfast, Belfast, UK,11Department of Oncology, University of Torino, Italy,12Belfast Health and Social Care Trust, Belfast, UK,13University Paris Descartes, Paris, France,14University of Oxford, Department of Oncology, Oxford, UK

Sensitizing p53 mutant HNSCC to oncolytic reovirus (RT3D) by targeting the ER stress response

Year:

Session type:

Theme:

Martin McLaughlin1,Victoria Roulstone1,Joan Kyula1,Magnus Dillon1,Alan Melcher1,Kevin Harrington1
1The Institute of Cancer Research London

COMBINED COPY NUMBER AND GENE EXPRESSION PROFILING IN HIGH RISK NEUROBLASTOMA: A CCLG PILOT BIOLOGICAL STUDY

Year:

Session type:

Theme:

Alem Gabriel1,Lindi Chen1,Laura Evans2,Sirintra Nakjang1,Nick Bown3,Daniel Williamson1,Deborah Tweddle1
1Newcastle University,2Dana-Farber Cancer Institute,3Northern Genetics Service

Coxsackievirus A21- A potential novel immunotherapy for bladder cancer

Year:

Session type:

Theme:

Mehreen Arif1
1University of Surrey

Current UK practice in palliative treatment of muscle invasive bladder cancer (MIBC) and impact on design of the phase III HYBRID adaptive image guided radiotherapy (IGRT) trial

Year:

Session type:

Theme:

Rebecca Lewis1,Joanna Illambas1,Ann Henry2,Syed Ali Moinuddin3,Helen Mossop1,Emma Hall1,Robert Huddart1,O n behalf of the HYBRID Trial Management Group4
1The Institute of Cancer Research,2Leeds Teaching Hospitals NHS Trust,3University College Hospital,4-

Nivolumab in patients with advanced NSCLC and central nervous system (CNS) metastases

Year:

Session type:

Theme:

Jonathan Goldman1,Lucio Crino2,Everett Vokes3,Esther Holgado4,Karen Reckamp5,Adam Pluzanski6,David Spigel7,Martin Kohlhaeufl8,Marina Garassino9,Laura Chow10,Scott Gettinger11,David Gerber12,Libor Havel13,Suresh Ramalingam14,Grace Dy15,William Geese16,Ang Li16,Anne Blackwood-Chirchir17,Diane Healey16,Julie Brahmer18
1UCLA Jonsson Comprehensive Cancer Center,2Medical Oncology, S. Maria della Misericordia Hospital,3Department of Medicine, University of Chicago,4Centro Integral Oncologico Clara Campal,5City of Hope,6Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,7Sarah Cannon Research Institute/Tennessee Oncology, PLLC,8Hospital Schillerhoehe Gerlingen, Center of Pneumonology and Chest Surgery,9Fondazione IRCCS Istituto Nazionale Dei Tumori,10Seattle Cancer Care Alliance,11Yale Comprehensive Cancer Center,12The University of Texas Southwestern Medical Center,133rd Medical Faculty, Charles University, Hospital Bulovka,14The Winship Cancer Institute of Emory University,15Roswell Park Cancer Institute,16Bristol-Myers Squibb,17Innovators BioPharma Consulting LLC,18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Efficacy of Carboplatin in oesophago-gastric cancer:The West Suffolk experience

Year:

Session type:

Theme:

Daniel Patterson1,Mario Alexander2
1West Suffolk Hospital,2University of Cambrige

Transient Surge in Carinoembryonic Antigen Levels During Adjuvant Chemotherapy for Colorectal Cancer is Not Associated with Relapse

Year:

Session type:

Theme:

Haixi Yan1,David Propper2,Mark Nathan2
1Barts Health NHS Trust,2Barts Cancer Institute, London, UK

To evaluate the accuracy of preoperative standard MRI scan in local staging of prostate cancer.

Year:

Session type:

Theme:

Mohanarangam Thangavelu1,Dumitru Butu2,Baha Qarini2,K Alexandrou2,E Ahiaku2
1Ysbyty Gwynedd,,2Ysbyty Gwynedd

SPORT High-Risk Trial: A Randomised Feasibility Study Evaluating Stereotactic PrOstate RadioTherapy in High-Risk Localised Prostate Cancer with or without Elective Nodal Irradiation

Year:

Session type:

Theme:

Ciara Lyons1,Conor McGarry2,Alan Hounsell2,Sharon Hynds2,Kevin Prise3,Joe O'Sullivan3,Suneil Jain3
1Centre for Cancer Research and Cell Biology,2Northern Ireland Cancer Centre, Belfast Health and Social Care Trust,3Centre for Cancer Research and Cell Biology, Queen's University Belfast

Cervical Cancer Screening in HIV Positive Women

Year:

Session type:

Theme:

Samantha Gaffing1,Nadi Gupta2
1Rotherham, Doncaster, South Humberside NHS Foundation Trust,2The Rotherham NHS Foundation Trust

Preclinical investigations of the potential of PARP and ATR inhibitors in ovarian cancer

Year:

Session type:

Theme:

Laurence Baker1,Elizabeth Matheson2,Mohammadreza Salehan2,Nicola J Curtin2,Yvette Drew2
1The University of Newcastle, Northern Institute of Cancer Research,2Northern Institute for Cancer Research, Newcastle University

Evaluation of sentinel lymph node metastatic deposit size and extracapsular spread on further axillary spread in breast cancer patients.

Year:

Session type:

Theme:

Eline Caine1,Thomas Newman2,Veronika Pronisceva1,Anil Poddar1,Elizabeth Sharp1
1East Kent Hospitals University NHS Foundation Trust,2Brighton and Sussex University Hospitals NHS Trust

Randomised trial to investigate two different schedules of nab-paclitaxel combined with gemcitabine as first line treatment for pancreatic cancer: delivering end-points of the SIEGE trial protocol

Year:

Session type:

Theme:

Pippa Corrie1,Burcu Babaoglan2,Wendi Qian2,James Mair2,Katy Dalchau2,Andrea Machin2,Aarthi Gopinathan3,Bristi Basu4,Duncan Jodrell4,Juan Valle5,Anita Chhabra2,Stephen Falk6,Edwina Scott7,Harpreet Wasan8,Daniel Palmer9,Martin Scott-Brown10,Jon Wadsley11,Seema Arif12,John Bridgewater13,David Propper14,Roopinder Gillmore15,Karen McAdam16,Sebastian Cummins17
1Cambridge University Hospitals NHS Foundation Trust, UK,2Cambridge University Hospitals NHS Foundation Trust,3Cancer Research UK Cambridge Institute,4Cancer Research UK Cambridge Institute / Cambridge University Hospitals NHS Foundation Trust,5University of Manchester/The Christie Hospital, Manchester, UK,6Bristol Haematology and Cancer Centre,7Leicester Royal Infirmary,8Hammersmith Hospital,9Clatterbridge Centre for Oncology,10Uni. Hospitals Coventry & Warwickshire,11Weston Park Hospital,12Velindre Cancer Centre,13UCLH,14Bart’s Health,15Royal Free Hospital,16Peterborough City Hospital,17Royal Surrey Hospital

How reliable is data collected in clinical trials? Experience of safety monitoring in the SIEGE pancreatic cancer clinical trial

Year:

Session type:

Theme:

Pippa Corrie1,Lorna Radford2,James Mair3,Burcu Babaoglan3,Wendi Qian3,Katy Dalchau3,Andrea Machin3,Aarthi Gopinathan4,Bristi Basu5,Duncan Jodrell5,Anita Chhabra3,Alkida Bucaj3,Claire Taylor6,Emily Foulstone7,Elizabeth Andrzejewski8,Mohana Suppiah9,Linda Lyons10,Lesley Hayward11,Cyper Allan12,Emma John13,Chris Wanstall14,Hannah Payne15,Sara Chamberlain16,Malwina Hartley17,Mahomed Moosa18
1Cambridge University Hospitals NHS Foundation Trust, UK,2University of Cambridge Medical School,3Cambridge University Hospitals NHS Foundation Trust,4Cancer Research UK Cambridge Institute,5Cancer Research UK Cambridge Institute / Cambridge University Hospitals NHS Foundation Trust,6University of Manchester/The Christie Hospital, Manchester,7Bristol Haematology and Cancer Centre,8Leicester Royal Infirmary,9Hammersmith Hospital,10Clatterbridge Centre for Oncology,11Uni. Hospitals Coventry & Warwickshire,12Weston Park Hospital, Sheffield,13Velindre Cancer Centre,14UCLH,15Bart’s Health,16Royal Free Hospital,17Peterborough City Hospital,18Royal Surrey Hospital

The changing face of metastatic breast cancer: A Sussex perspective

Year:

Session type:

Theme:

Gargi Patel1,Aspasia Soultati2,Richard Simcock1,Sarah Westwell3,David Bloomfield1,Rajesh Sinha1,Adrian Moss4,Charlotte Moss3
1Brighton and Susex University Hospitals Trust,2Royal Susex County Hospital, Brighton,3East Sussex Healthcare NHS Trust,4Western Sussex Hospitals

Surgical Outcome of Gastrointestinal Lymphoma: Experience from a Tertiary Care Center of North India

Year:

Session type:

Theme:

Anand Prakash1,Sandeep Verma2,Ashok Kumar2,Vinay K Kapoor2,Rajan Saxena2
1Sanjay Gandhi Postgraduate Institute of Medical Sciences,2SGPGIMS Lucknow India

Optimisation of the PIG-A test: a diagnostic predictor of oesophageal adenocarcinoma development.

Year:

Session type:

Theme:

Rachel Lawrence1,Hasan Haboubi2,Lisa Williams3,Shareen Doak1,Gareth Jenkins1
1Swansea University Medical school,2Swansea University Medical School,3Singleton Hospital ABMU Health board

Three dose-level prostate SBRT: a feasibility study

Year:

Session type:

Theme:

Adam Mitchell1,Linus Benjamin1,Nicholas Van As1,Alison Tree1
1Royal Marsden NHS Foundation Trust

4 years’ experience with HDR prostate brachytherapy boost- toxicity and biochemical control

Year:

Session type:

Theme:

Elizabeth Crolla1,Chris Lee2,Andrea Law3,Lucy Partridge2,Isabel Syndikus1,Chinnamani Eswar1
1Radiotherapy Department, Clatterbridge Cancer Centre,2Medical Physics Department, Clatterbridge Cancer Centre,3Clinical Effectiveness Team, Clatterbridge Cancer Centre

Molecular characterization of PD-L1 status on circulating tumour cells (CTCs) isolated from patients with advanced cancers

Year:

Session type:

Theme:

Zai Ahmad1,Jen Fraser-Fish1,Rajiv Kumar2,Bernadette Ebbs1,Gemma Fowler1,Penny Flohr1,Mateus Crespo1,Marina Ahmad2,Sanjay Popat2,Jaishree Bhosle2,Udai Banerji3,Mary O'Brien2,Johann de Bono3,Timothy Yap3
1The Institute of Cancer Research,2The Royal Marsden NHS Foundation Trust,3The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

A comparison of 4DCT-derived and 4D-PET-CT-derived planning target volumes for oesophageal cancer patients

Year:

Session type:

Theme:

Ganesh Radhakrishna1,Patrick Murray1,Rebecca Goody1,Andrew Scarsbrook1,Robin Prestwich1,Sarah Wright1,Garry McDermott1,Ganesh Radhakrishna1
1Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust

Clinical decision making in patients with Metastatic Breast Cancer in the United Kingdom (UK) and Italy

Year:

Session type:

Theme:

Maria Jove1,Laura Ferrari2,Lorenzo Gerratana2,Marta Bonotto2,Marika Cinausero2,Fabio Puglisi2,Chris Twelves1
1Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds,2Department of Oncology, University and General Hospital, Udine, Italy

Research Database of Sequential Mammography Screening events: a source of big data to investigate changes to routine screening

Year:

Session type:

Theme:

Mishal Patel1,Ken Young1,Mark Halling-Brown1
1Royal Surrey County Hospital

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

Year:

Session type:

Theme:

Nicola Curtin1,Elizabeth Matheson2,Mohammadreza Salehan2,Asima Mukhopadhyay2,Yvette Drew2
1University of Newcastle,2Newcastle University

Accelerating Phase I oncology trials, knowing when to apply the safety brakes: the experience of CR UK Centre for Drug Development (CDD) Study management.

Year:

Session type:

Theme:

Susan Wan1,Louisa Essame1,Helen Turner1,Claire Goff1,Sarah Potter1,Lesley Mcguigan1,Mark Webster Smith1,Karen Dyer1
1Cancer Research UK, Centre for Drug Development

Associations between oncogenic mutations: A possible underlying cause of heterogeneous responses to chemotherapy in patients with advanced colorectal cancer.

Year:

Session type:

Theme:

Susan Richman1,Henry Wood2,Morag Taylor2,Gemma Hemmings2,Philip Chambers2,Richard Adams3,Rachel Butler4,Joseph Foster5,Karen Spink5,Timothy Maughan6,Philip Quirke2
1Leeds Teaching Hospitals NHS Trust,2University of Leeds,3Velindre Hospital,4University Hospital of Wales,5Affymetrix,6CRUK/MRC Oxford Institute for Radiation Oncology

POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis

Year:

Session type:

Theme:

Enric Domingo1,Luke Freeman-Mills1,Emily Rayner1,Mark Glaire1,Sarah Briggs1,Louis Vermeulen2,Eve Fessler2,Tom van Wezel3,Gerrit-Jan Leifers3,Ragnhild Lothe4,Stine Danielsen4,Arild Nesbakken4,Inti Zlobec5,Viktor Koelzer5,Sergi Castellvi-Bel6,Jenifer Muñoz6,Marco de Bruyn7,Marco Novelli8,Kay Lawson8,Dahmane Oukrif8,Sabine Tejpar9,Mauro Delorenzi10,Rachel Kerr1,David Kerr1,Ian Tomlinson1,David Church1
1University of Oxford,2Academic Medical Center Amsterdam,3Leiden University Medical Center,4Oslo University Hospital,5University of Bern,6Institut d’Investigacions Biomèdiques August Pi i Sunyer,7University Medical Center Groningen,8University College London,9University of Leuven,10University of Lausanne

Evaluation of immune checkpoint marker co-expression profiles in the tumor microenvironment

Year:

Session type:

Theme:

Morgane Rouault1,Emily Park1,Jeff Kim1,Na Li1,Xiao-Jun Ma1
1Advanced Cell Diagnostics

Designing a practice-changing trial for a rare cancer population: The Rational MCC trial of first definitive treatment for Merkel cell carcinoma

Year:

Session type:

Theme:

Rachel Blundred1,Christina Yap2,Carie Corner3,Pat Lawton4,Oliver Cassell5,Clair McGarr6,Ian Zealley7,Sarah Pirrie1,Sarah Bowden1,Jaspreet Babrah1,Simon Rodwell8,Catherine Harwood9,Neil Steven10
1CR-UK Clinical Trials Unit, The University of Birmingham,2The University of Birmingham, UK,3East and North Herts NHS Trust,4Nottingham University Hospital NHS Trust, Nottingham,5Oxford University Hospitals NHS Trust,6University Hosp[ital Birmingham NHS Trust,7NHS Tayside,8Melanoma Focus,9Queen Mary University of London,10University of Birmingham